Semaglutide vs CagriSema.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation. It is a fully approved prescription medicine marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and, more recently, cardiovascular risk reduction). It is one of the most extensively studied peptide therapeutics in modern medicine, with large dedicated cardiovascular- and liver-outcome trials.

CagriSema is a fixed-combination injectable investigational obesity therapeutic developed by Novo Nordisk that co-formulates two long-acting peptide analogues in a single once-weekly subcutaneous injection: cagrilintide, a long-acting amylin receptor agonist (analogue of the pancreatic hormone amylin), and semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist already marketed for diabetes and obesity. It pairs the same semaglutide molecule found in Ozempic and Wegovy with a novel amylin analogue, making it the first amylin-plus-GLP-1 dual-hormone combination to reach late-stage clinical development for weight management.

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, and elsewhere. In the pancreas it augments glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose with low intrinsic hypoglycemia risk because the effect is glucose-dependent. Centrally, it acts on hypothalamic and hindbrain appetite circuits to increase satiety and reduce food intake, and it slows gastric emptying; the combination drives weight loss. The molecule's C18 fatty-diacid side chain promotes albumin binding, which extends its half-life to roughly a week and underlies once-weekly dosing.

The two components act on complementary appetite-regulating pathways. Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and signals through hypothalamic and brainstem circuits to reduce hunger and increase satiety. Cagrilintide is an amylin analogue that engages amylin and calcitonin-family receptors, also acting on the area postrema and hypothalamus to promote satiation and reduce food intake; amylin signaling is thought to modulate leptin sensitivity and meal termination through a partly distinct mechanism from GLP-1. The rationale is that combining the two yields additive or complementary reductions in energy intake beyond either agent alone.

Human evidence is exceptionally strong and trial-backed rather than preclinical. The STEP 1 randomized trial (NEJM 2021, PMID 33567185) showed substantial, clinically meaningful weight loss versus placebo in adults with overweight/obesity without diabetes. SUSTAIN-6 (NEJM 2016, PMID 27633186) demonstrated reduced major adverse cardiovascular events in type 2 diabetes, and SELECT (NEJM 2023, PMID 37952131) showed a significant reduction in cardiovascular death, myocardial infarction, or stroke in people with obesity and established cardiovascular disease but without diabetes. The phase 3 ESSENCE trial (NEJM 2025, PMID 40305708) reported improvement in metabolic dysfunction-associated steatohepatitis (MASH). A documented limitation: the STEP 1 extension (Diabetes Obes Metab 2022, PMID 35441470) showed substantial weight regain after discontinuation, indicating benefits depend on continued use.

Unlike most "research peptides," CagriSema has substantial human Phase 3 data from the REDEFINE program. In REDEFINE 1 (Garvey et al., NEJM 2025; 68 weeks, ~3,400 adults with obesity/overweight without diabetes), CagriSema produced roughly 20% mean body-weight loss versus semaglutide alone, cagrilintide alone, and placebo. In REDEFINE 2 (Davies et al., NEJM 2025), conducted in adults with overweight/obesity and type 2 diabetes, CagriSema reduced body weight and HbA1c versus placebo, though weight loss in the diabetes population was more modest, consistent with the general pattern for incretin therapies. REDEFINE 5 (Yamauchi et al., Lancet Diabetes & Endocrinology 2026) evaluated it versus semaglutide alone in Japan and Taiwan. Importantly, in the open-label head-to-head REDEFINE 4 trial, CagriSema (~23% weight loss on the efficacy estimand) did NOT meet its primary endpoint of non-inferiority versus tirzepatide (Zepbound, ~25.5%), a notable negative result that tempers claims of clear superiority over existing dual/incretin therapies.

The most common documented adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, typically most pronounced early in treatment. Labeled warnings include a boxed warning for thyroid C-cell tumors based on rodent data (clinical relevance in humans remains uncertain), plus risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, and diabetic retinopathy complications in susceptible patients. Reduced lean mass alongside fat loss, and weight regain after stopping, are recognized. Use of unregulated, compounded, or research-grade "semaglutide" sold outside the approved supply chain carries additional, poorly characterized risks of contamination, mislabeling, and dosing errors.

The most common adverse events in the REDEFINE trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the known class effects of GLP-1 receptor agonists and amylin analogues; these were generally mild-to-moderate and most frequent during dose escalation. As with other GLP-1-based therapies, label-level concerns for the class include gallbladder events, pancreatitis risk signals, and a boxed thyroid C-cell tumor warning carried by semaglutide products (based on rodent data). Long-term safety, durability after discontinuation, and outcomes in broader real-world populations remain incompletely characterized because the compound is still investigational and only recently filed for approval. No legitimate medical use exists outside clinical trials and (pending) regulatory approval, and gray-market "research" cagrilintide/semaglutide products carry purity, sterility, and dosing-error risks.

Semaglutide is FDA-approved (not investigational): Ozempic and Rybelsus for type 2 diabetes with cardiovascular risk-reduction indications, and Wegovy for chronic weight management and for cardiovascular risk reduction in adults with cardiovascular disease and overweight/obesity. Oral semaglutide for chronic weight management and a MASH indication are the most recent regulatory developments.

CagriSema is investigational and not approved by the FDA or EMA as of mid-2026; Novo Nordisk submitted a U.S. New Drug Application for chronic weight management on December 18, 2025, with a regulatory decision anticipated in late 2026. Its individual components have separate statuses: semaglutide is FDA-approved (e.g., Wegovy, Ozempic), while cagrilintide alone is not approved.